RxDoctor Payments Data

Rocco Caruso, MD

Hematology & Oncology · East Setauket, NYNPI 1285630731

Payments from drug & device makers

$252in general payments, 2019–2025

Across 15 payments — averaging $16.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$135
  • Alnylam Pharmaceuticals Inc.$21
  • CSL Behring$20
  • Merck$19
  • Sanofi$19
  • Sirtex Medical Inc$14
  • plus $24 from 2 others

What the payments were for

  • Food & beverage$23292%
  • Education$208%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$252 in reported general payments places this provider in the 15th percentile of 967 hematology & oncology providers in New York.

See all hematology & oncology providers in New York

Medicare billing

Part B allowed, 2024
$3,034,268
Medicare patients
1,579
Services billed
178,154

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib55$926,492
CalquenceAcalabrutinib Maleate40$590,443
RevlimidLenalidomide38$560,172
AranespDarbepoetin Alfa In Polysorbat155$556,830
IbrancePalbociclib36$541,284
VerzenioAbemaciclib20$296,002
ReblozylLuspatercept-Aamt21$268,904
BrukinsaZanubrutinib18$258,052
Darzalex FasproDaratumumab-Hyaluronidase-Fihj18$254,179
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5066$251,145
TasignaNilotinib Hcl12$232,443
RiabniRituximab-Arrx39$228,929
OctagamImmun Globg(Igg)/Malt/Iga Ov5032$218,018
PomalystPomalidomide17$213,296
Lupron DepotLeuprolide Acetate59$196,808

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisTasigna, Sandostatin Lar Depot$11$338,95635 claims
Lilly USA, LLCVerzenio$12$296,00220 claims
CSL BehringPrivigen$20$131,01415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 967 hematology & oncology providers in New York.

Other hematology & oncology in East Setauket

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →